

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/246863 A1

(51) International Patent Classification:
C07D 235/08 (2006.01) A61P 35/00 (2006.01)
C07D 403/12 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/IB2024/055354

(22) International Filing Date:
31 May 2024 (31.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/505,508 01 June 2023 (01.06.2023) US
63/583,600 19 September 2023 (19.09.2023) US

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(71) Applicants: **GLAXOSMITHKLINE INTELLECTUAL
PROPERTY (NO.4) LIMITED** [GB/GB]; GSK Med-
icines Research Centre, Gunnels Wood Road, Steve-
nage SG1 2NY (GB). **IDEAYA BIOSCIENCES, INC.**
[US/US]; 7000 Shoreline Court, Suite 350, South San Fran-
cisco, California 94080 (US).

(72) Inventors: **DEMARTINO, Michael P.**; 1250 South Col-
legeville Road, Collegeville, Pennsylvania 19426 (US).
BRNARDIC, Edward; 1250 South Collegeville Road,
Collegeville, Pennsylvania 19426 (US). **PHELAN, James
P.**; 1250 South Collegeville Road, Collegeville, Pennsyl-
vania 19426 (US). **CAMPBELL, Kira A.**; 1250 South
Collegeville Road, Collegeville, Pennsylvania 19426 (US).
JONES, Brian T.; 7000 Shoreline Court, South San Fran-
cisco, California 94080 (US). **TAYGERLY, Joshua P.G.**;
7000 Shoreline Court, South San Francisco, California
94080 (US). **RYAN, Jonathon S.**; 7000 Shoreline Court,
Suite 350, South San Francisco, California 94080 (US).
SEVERANCE, Daniel L.; 8439 Torrell Way, San Francis-
co, California 92126 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CHEMICAL COMPOUNDS AND USES THEREOF

(57) Abstract: Disclosed herein are certain chemical compounds that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are therefore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.



WO 2024/246863 A1